The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Paclitaxel

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Paclitaxel.
Marina Chiara Garassino
Connection Strength
0.681
Paclitaxel
  1. Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018 10 15; 78(20):5729-5730.
    View in: PubMed
    Score: 0.538
  2. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
    View in: PubMed
    Score: 0.060
  3. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
    View in: PubMed
    Score: 0.049
  4. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.